Literature DB >> 22327841

Invasive aspergillosis: resistance to antifungal drugs.

Inès Hadrich1, Fattouma Makni, Sourour Neji, Salma Abbes, Fatma Cheikhrouhou, Houaida Trabelsi, Hayet Sellami, Ali Ayadi.   

Abstract

Although the arsenal of agents with anti-Aspergillus activity has expanded over the last decade, mortality due to invasive aspergillosis remains unacceptably high. Resistance of the Aspergillus spp. species to antifungal drugs increased in the last 20 years with the increase in antifungal drugs use and might partially account for treatment failures. Recent advances in our understanding of mechanisms of antifungal drug action in Aspergillus, along with the standardization of in vitro susceptibility testing methods, have brought resistance testing to the forefront of clinical mycology. Recent modifications in taxonomy and understanding of the acquired resistance mechanisms of Aspergilli to drugs should support a better management of Aspergillus infections. In this paper, we review the current knowledge on epidemiology and underlying mechanisms involved in antifungal resistance in Aspergillus.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22327841     DOI: 10.1007/s11046-012-9526-y

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  47 in total

Review 1.  Invasive aspergillosis in 2002: an update.

Authors:  D P Kontoyiannis; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-03-22       Impact factor: 3.267

Review 2.  Antifungal agents: mechanisms of action.

Authors:  Frank C Odds; Alistair J P Brown; Neil A R Gow
Journal:  Trends Microbiol       Date:  2003-06       Impact factor: 17.079

3.  In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.

Authors:  Alicia Gomez-Lopez; Guillermo Garcia-Effron; Emilia Mellado; Araceli Monzon; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

4.  Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole.

Authors:  Ricardo Araujo; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

5.  Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing.

Authors:  V Buchta; M Vejsova; L A Vale-Silva
Journal:  Folia Microbiol (Praha)       Date:  2008       Impact factor: 2.099

6.  Invasive aspergillosis: epidemiology and environmental study in haematology patients (Sfax, Tunisia).

Authors:  I Hadrich; F Makni; H Sellami; F Cheikhrouhou; A Sellami; H Bouaziz; S Hdiji; M Elloumi; A Ayadi
Journal:  Mycoses       Date:  2009-06-04       Impact factor: 4.377

7.  Nonsporulating clinical isolate identified as Petromyces alliaceus (anamorph Aspergillus alliaceus) by morphological and sequence-based methods.

Authors:  S Arunmozhi Balajee; Mark D Lindsley; Naureen Iqbal; James Ito; Peter G Pappas; Mary E Brandt
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

8.  Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent.

Authors:  Tamara Koss; Bita Bagheri; Cosmina Zeana; Mario F Romagnoli; Marc E Grossman
Journal:  J Am Acad Dermatol       Date:  2002-06       Impact factor: 11.527

9.  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Authors:  Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

10.  In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.

Authors:  Jesús Guinea; Teresa Peláez; Sandra Recio; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.938

View more
  6 in total

Review 1.  Immunotherapy for opportunistic infections: Current status and future perspectives.

Authors:  Shigeo Fuji; Jürgen Löffler; Hermann Einsele; Markus Kapp
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

2.  A 76-year-old man with a right lung adenocarcinoma and invasive Aspergillosis.

Authors:  Vitorino Modesto Dos Santos; Marcos Correa da Trindade; Diogo Wagner da Silva de Souza; Ana Isabel Costa de Menezes; Patricia Midori Oguma; Afonso Lucas Oliveira Nascimento
Journal:  Mycopathologia       Date:  2013-04-25       Impact factor: 2.574

3.  Two C4-sterol methyl oxidases (Erg25) catalyse ergosterol intermediate demethylation and impact environmental stress adaptation in Aspergillus fumigatus.

Authors:  Sara J Blosser; Brittney Merriman; Nora Grahl; Dawoon Chung; Robert A Cramer
Journal:  Microbiology (Reading)       Date:  2014-08-08       Impact factor: 2.777

4.  In vitro susceptibility to amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin of Aspergillus spp. isolated from patients with haematological malignancies in Tunisia.

Authors:  Soukeina Gheith; Fatma Saghrouni; Wadiaa Bannour; Yosra Ben Youssef; Abderrahim Khelif; Anne-Cécile Normand; Renaud Piarroux; Moncef Ben Said; Mansour Njah; Stéphane Ranque
Journal:  Springerplus       Date:  2014-01-10

5.  In vivo efficacy of a synthetic coumarin derivative in a murine model of aspergillosis.

Authors:  Seema Singh; Rajesh Dabur; Madhumanjiri M Gatne; Bharat Singh; Shilpi Gupta; Sharad Pawar; Sunil K Sharma; Gainda L Sharma
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

6.  A computational model of invasive aspergillosis in the lung and the role of iron.

Authors:  Matthew Oremland; Kathryn R Michels; Alexandra M Bettina; Chris Lawrence; Borna Mehrad; Reinhard Laubenbacher
Journal:  BMC Syst Biol       Date:  2016-04-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.